Advertisement

International Journal of Clinical Pharmacy

, Volume 36, Issue 2, pp 438–442 | Cite as

Results of intravitreal triamcinolone acetonide in patients with macular edema secondary to branch retinal vein occlusion

  • Mehmet DemirEmail author
  • Ersin Oba
  • Dilek Guven
  • Zeynep Acar
  • Sonmez Cinar
Research Article

Abstract

Background Macular edema is one of the most common causes of visual loss in patients with retinal vein oclusions. Intravitreal corticosteroids and intravitreal anti-vascular endothelial growth factors are modalities of treatment for macular edema secondary to branch retinal vein occlusion (BRVO). Objective To present the results of intravitreal triamcinolone acetonide therapy in patients with macular edema secondary to BRVO. Setting A retrospective clinical interventional study included 32 patients with macular edema secondary to BRVO. Method The records of 32 eyes of 32 patients who received 4 mg/0.1 mL injection of intravitreal triamcinlone for macular edema secondary to BRVO were evaluated. Patients with visual acuity <0.40 logMAR (logarithm of the minimum angle of resolution), central macular thickness (CMT) >260 μm and no neovascularization at baseline were included. Patients with diabetes mellitus, a history of intravitreal anti vascular endothelial growth factor injection, grid laser photocoagulation and ischemic BRVO were excluded. The re-injections were performed in cases with increased CMT >100 μm or vision loss of five or more letters. Results The mean follow-up was 12 ± 1.9 months. The visual acuity increased from 0.58 ± 0.16 at baseline to 0.25 ± 0.11 logMAR (P < 0.001). The CMT decreased from 490 ± 107 μm at baseline to 266 ± 90 μm at 12 months (P < 0.001). Both cataract and glaucoma developed in 18.75 % patients. Conclusion Intravitreal triamcinolone, due to absence of systemic side effects, can be used with confidence for treatment macular edema secondary to BRVO. However the main disadvantages of intravitreal triamcinolone injection are elevation of intraocular pressure and formation of cataract.

Keywords

Branch retinal vein occlusion Intravitreal triamcinolone Macular edema 

Notes

Acknowledgments

The authors would like to thank the clinical secretaries for their assistance.

Funding

None.

Conflicts of interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Cugati S, Wang JJ, Rochtchine E, Mitchell P. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountain Eye study. Arch Ophthalmol. 2006;124(5):726–32.PubMedCrossRefGoogle Scholar
  2. 2.
    Hayreh SS, Zimmerman B, Mc Carthy MJ, Podhajsky P. Systemic diseases associated with various types of retinal occlusion. Am J Ophthalmol. 2001;131(1):61–77.PubMedCrossRefGoogle Scholar
  3. 3.
    Blond J, Glacet-Bernard A, Bayani N, Blacher J, Lelong F, Nordmann JP, et al. Retinal vein occlusion and hyperhomocysteinemia. J Fr Opthalmol. 2003;26(3):249–53.Google Scholar
  4. 4.
    Rath EZ, Frank RN, Shin DH, Kim C. Risk factors for retinal vein occlusion. A case–control study. Ophthalmology. 1992;99(4):509–14.PubMedCrossRefGoogle Scholar
  5. 5.
    Aref AA, Scott IU. Management of macular edema secondary to branch retinal vein occlusion: an evidence-based update. Adv Ther. 2011;28(1):28–39.PubMedCrossRefGoogle Scholar
  6. 6.
    Cheng KC, Wu WC, Chen KJ. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion. Eye (Lond). 2009;23(11):2023–33.CrossRefGoogle Scholar
  7. 7.
    Higashiyama T, Sawada O, Kakinoki M, Sawada T, Kawamura H, Ohji M. Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion. Acta Ophthalmol. 2013;91(4):318–24.PubMedCrossRefGoogle Scholar
  8. 8.
    Aiello LP, Avery RL, Arrig PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Funk M, Kriechbaum K, Prager F, Benesch T, Georgopoulos M, Zlabinger GJ, et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Investig Ophthalmol Vis Sci. 2009;50(3):1025–32.CrossRefGoogle Scholar
  10. 10.
    Kaneda S, Miyazaki D, Sasaki S, Yakura K, Terasaka Y, Miyake K, et al. Multivariate analyses of inflammatory cytokines in eyes with branch retinal vein occlusion: relationships to bevacizumab treatment. Investig Ophthalmol Vis Sci. 2011;52(6):2982–8.CrossRefGoogle Scholar
  11. 11.
    Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T, et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye (Lond). 2008;22(1):42–8.CrossRefGoogle Scholar
  12. 12.
    Branch Retinal Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984;98(3):271–82.Google Scholar
  13. 13.
    Akduman L, Olk RJ. Subthreshold (invisible) modified grid diode laser photocoagulation in diffuse diabetic macular edema (DDME). Ophthal Surg Lasers. 1999;30(9):706–14.Google Scholar
  14. 14.
    Channa R, Smith M, Campochiaro PA. Treatment of macular edema due to retinal vein occlusions. Clin Ophthalmol. 2010;5:705–13.Google Scholar
  15. 15.
    Holladay JT. Visual acuity measurements. J Cataract Refract Surg. 2004;30(2):287–90.PubMedCrossRefGoogle Scholar
  16. 16.
    Demir M, Oba E, Gulkilik G, Odabasi M, Ozdal E. Intravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month results. Clin Ophthalmol. 2011;5:745–9.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Kriechbaum K, Michels S, Prager F, Georgopoulos M, Funk M, Geitzenauer W, et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol. 2008;92(4):518–22.PubMedCrossRefGoogle Scholar
  18. 18.
    Byun YJ, Roh MI, Lee SC, Koh HJ. Intravitreal triamcinolone acetonide versus bevacizumab therapy for macular edema associated with branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2010;248(7):963–71.PubMedCrossRefGoogle Scholar
  19. 19.
    Carneiro AM, Barthelmes D, Falcao MS, Mendonca LS, Fonseca SL, Goncalves RM, et al. Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. Ophthalmologica. 2011;225(4):211–21.PubMedCrossRefGoogle Scholar
  20. 20.
    Ding X, Li J, Hu X, Yu S, Pan J, Tang S. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Retina. 2011;31(5):838–45.PubMedCrossRefGoogle Scholar
  21. 21.
    Tao Y, Hou J, Jiang YR, Li XX, Jonas JB. Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Eye (Lond). 2010;24(5):810–5.CrossRefGoogle Scholar
  22. 22.
    Cekic O, Cakır M, Yazıcı AT, Alagöz N, Bozkurt E, Faruk OF. A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion. Curr Eye Res. 2010;35(10):925–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Cakir M, Dogan M, Bayraktar Z, Bayraktar S, Acar N, Altan T, et al. Efficacy of intravitreal triamcinolone for the treatment of macular edema secondary to branch retinal vein occlusion in eyes with or without grid laser photocoagulation. Retina. 2008;28(3):465–72.PubMedCrossRefGoogle Scholar
  24. 24.
    Noma H, Funatsu H, Mimura T, Shimada K. Functional-morphological changes after ıntravitreal ınjection of triamcinolone acetonide for macular edema with branch retinal vein occlusion. J Ocul Pharmacol Ther. 2012;28(3):231–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Chen SD, Sundaram V, Lochhead J, Patel CK. Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion. Am J Ophthalmol. 2006;141(5):876–83.PubMedCrossRefGoogle Scholar
  26. 26.
    Vasconcelos-Santos DV, Nehemy PG, Schachat AP, Nehemy MB. Secondary ocular hypertension after intravitreal injection of 4 mg of triamcinolone acetonide: incidence and risk factors. Retina. 2008;28(4):573–80.PubMedCrossRefGoogle Scholar
  27. 27.
    Prager F, Michels S, Kriechbaum K, Georgopoulos M, Funk M, Geitzenauer W, Polak K, et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of prospective clinical trial. Br J Ophthalmol. 2009;93(4):452–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Ahmadi AA, Chuo JY, Banashkevich A, Ma PE, Maberley DA. The effects of intravitreal bevacizumab on patients with macular edema secondary to branch retinal vein occlusion. Can J Ophthalmol. 2009;44(2):154–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Kim JY, Park SP. Comparison between intravitreal bevacizumab and triamcinolone for macular edema secondary to branch retinal vein occlusion. Korean J Ophthalmol. 2009;23(4):259–65.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Hou J, Tao Y, Jiang YR, Li XX, Gao L. Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: a matched study. Chin Med J (Engl). 2009;122(22):2695–9.PubMedGoogle Scholar
  31. 31.
    Rezende MP, Dias AF, Oshima A, Andrade EP, Serracarbassa PD. Study of visual acuity and intraocular pressure in the treatment of macular diabetic edema with intravitreous triamcinolone. Arq Bras Oftalmol. 2010;73(2):129–34.PubMedCrossRefGoogle Scholar
  32. 32.
    Gillies MC, Islam FM, Larsson J, Pasadhika S, Gaston C, Zhu M, et al. Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective date from a randomised clinical trial. Clin Exp Ophthalmol. 2010;38(6):605–12.CrossRefGoogle Scholar
  33. 33.
    Islam MS, Vernon SA, Negi A. Intravitreal triamcinolone will cause posterior subcapsular cataract in most eyes with diabetic maculopathy within 2 years. Eye (Lond). 2007;21(3):321–3.CrossRefGoogle Scholar
  34. 34.
    Hanada N, Iijima H, Sakurada Y, Imasawa M. Recurrence of macular edema associated with branch retinal vein occlusion after intravitreal bevacizumab. Jpn J Ophthalmol. 2012;56(2):165–74.PubMedCrossRefGoogle Scholar

Copyright information

© Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2014

Authors and Affiliations

  • Mehmet Demir
    • 1
    Email author
  • Ersin Oba
    • 2
  • Dilek Guven
    • 1
  • Zeynep Acar
    • 1
  • Sonmez Cinar
    • 1
  1. 1.Department of OphthalmologySisli Etfal Training and Research HospitalIstanbulTurkey
  2. 2.Department of OphthalmologyKafkas UniversityKarsTurkey

Personalised recommendations